Código QR (código de barras bidimensional)

Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients

Abstract Introduction The majority of metastatic renal cell carcinoma (mRCC) patients receive one or more VEGFR TKI agents, alone or in combination with an immune-oncology (IO) agent or an mTOR inhibitor. To date, the cost of adverse events (AEs) common to VEGFR TKIs has not been quantified. This st...

Fuld beskrivelse

Na minha lista:
Principais autores: Jeffrey Thomas Yorio, Aviva G. Asnis-Alibozek, Vijay Kasturi, Thomas E. Hutson
Format: Artigo
Sprog:Inglês
Udgivet: BMC 2024-10-01
Serier:BMC Health Services Research
Fag:
Metastatic renal cell carcinoma
VEGFR tyrosine kinase inhibitor (TKI)
Adverse event
Claims analysis
Third-line treatment
Cost of care
Online adgang:https://doi.org/10.1186/s12913-024-11587-8
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker